[go: up one dir, main page]

NO20084999L - Fremgangsmate for behandling av arvelig hemokromatose - Google Patents

Fremgangsmate for behandling av arvelig hemokromatose

Info

Publication number
NO20084999L
NO20084999L NO20084999A NO20084999A NO20084999L NO 20084999 L NO20084999 L NO 20084999L NO 20084999 A NO20084999 A NO 20084999A NO 20084999 A NO20084999 A NO 20084999A NO 20084999 L NO20084999 L NO 20084999L
Authority
NO
Norway
Prior art keywords
treatment
hereditary hemochromatosis
procedure
compound
iron overload
Prior art date
Application number
NO20084999A
Other languages
English (en)
Inventor
Hanspeter Nick
Lisa Rojkjaer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38859061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084999(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20084999L publication Critical patent/NO20084999L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen er relatert for anvendelsen av forbindelse I av den følgende formelen i behandlingen av jernoverbelastning resulterende fra arvelig hemokromatose i pasient med behov for en slik behandling og til en kommersiell pakning omfattende forbindelse I sammen med instruksjoner for behandling av jernoverbelastning i pasienter med arvelig hemokromatose.
NO20084999A 2006-05-23 2008-11-28 Fremgangsmate for behandling av arvelig hemokromatose NO20084999L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74797406P 2006-05-23 2006-05-23
US80304906P 2006-05-24 2006-05-24
US83565806P 2006-08-04 2006-08-04
PCT/US2007/069319 WO2008005624A2 (en) 2006-05-23 2007-05-21 Method of treatment of hereditary hemochromatosis

Publications (1)

Publication Number Publication Date
NO20084999L true NO20084999L (no) 2008-12-23

Family

ID=38859061

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084999A NO20084999L (no) 2006-05-23 2008-11-28 Fremgangsmate for behandling av arvelig hemokromatose

Country Status (21)

Country Link
US (2) US20110105575A1 (no)
EP (2) EP2255805A1 (no)
JP (1) JP2009538329A (no)
KR (1) KR20080112407A (no)
AU (1) AU2007269536B2 (no)
BR (1) BRPI0712020A2 (no)
CA (1) CA2650433A1 (no)
CL (1) CL2007001456A1 (no)
DK (1) DK2026801T3 (no)
ES (1) ES2440806T3 (no)
HR (1) HRP20140096T1 (no)
IL (1) IL194659A0 (no)
MA (1) MA30432B1 (no)
MX (1) MX2008014837A (no)
NO (1) NO20084999L (no)
NZ (1) NZ572155A (no)
PL (1) PL2026801T3 (no)
PT (1) PT2026801E (no)
TN (1) TNSN08479A1 (no)
TW (1) TW200808745A (no)
WO (1) WO2008005624A2 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10694962B2 (en) 2011-06-13 2020-06-30 Cedars-Sinai Medical Center Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
WO2012174157A1 (en) 2011-06-13 2012-12-20 Cedars-Sinai Medical Center Assessment of iron deposition post myocardial infarction as a marker of myocardial hemorrhage
WO2024011188A1 (en) * 2022-07-07 2024-01-11 Protagonist Therapeutics, Inc. Combination therapy for treatment of iron overload diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AU2007269536B2 (en) 2011-06-30
US20110294861A1 (en) 2011-12-01
JP2009538329A (ja) 2009-11-05
BRPI0712020A2 (pt) 2011-12-27
DK2026801T3 (da) 2014-01-27
EP2255805A1 (en) 2010-12-01
MX2008014837A (es) 2008-12-01
TNSN08479A1 (en) 2010-04-14
US20110105575A1 (en) 2011-05-05
ES2440806T3 (es) 2014-01-30
AU2007269536A1 (en) 2008-01-10
KR20080112407A (ko) 2008-12-24
MA30432B1 (fr) 2009-05-04
NZ572155A (en) 2011-11-25
PL2026801T3 (pl) 2014-04-30
CA2650433A1 (en) 2008-01-10
PT2026801E (pt) 2014-02-06
HRP20140096T1 (hr) 2014-02-28
TW200808745A (en) 2008-02-16
EP2026801B1 (en) 2013-11-06
CL2007001456A1 (es) 2008-05-16
EP2026801A2 (en) 2009-02-25
WO2008005624A2 (en) 2008-01-10
IL194659A0 (en) 2009-08-03
WO2008005624A3 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
NO20072461L (no) Fremstilling og anvendelse av bifenyl-4-yl-karbonylaminosyre derivater for behandling av fedme
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
EA200800762A1 (ru) Предотвращение гипотензии и стабилизация кровяного давления у гемодиализных пациентов
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MY155255A (en) Spiro-oxindole compounds and their use as therapeutic agents
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
MX2008010931A (es) Quinolonas utiles como inhibidores de sintasa de oxido nitrico inducibles.
EA201000098A1 (ru) Производные хиназолинамида
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA200802329A1 (ru) Производные триазола ii
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
ATE444066T1 (de) Liganden für den cannabinoidrezeptoren
ATE517882T1 (de) Chinolinderivate
EA200801997A1 (ru) Новые соединения
EA201170521A1 (ru) Новые соединения
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX335941B (es) Inhibidores sustituidos de n-[1-ciano-2- (fenil) etil]-2-azabiciclo[2.2.1] heptan-3-carboxamida de catepsina c.
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
UA104148C2 (ru) [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1h-индол-3-ил]-метанон как ингибитор триптазы тучных клеток
MX2010001300A (es) Uso de hesperidina o un derivado de la misma para prevencion y/o tratamiento de pieles flacidas.
EA201170754A1 (ru) Способы профилактики или снижения канцерогенеза ободочной кишки
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application